Thursday, August 2, 2012

This Week’s IPOs: Biotechs and a Cloud Play

Last week we had 10 IPOs, with an average return of 16%.�Caesars (NASDAQ:CZR) was a big contributor — it soared 58.20%. But there were six other deals that saw double-digit returns as well:

companytickerreturn (%)
HomestreetHMST0.00
GSEGSE27.80
SynacorSYNC5.00
FX AllianceFX11.10
CaesarsCZR58.20
Cementos PacasmayoCPAC-4.30
ChemoCentryxCCXI11.30
EPAM SystemsEPAM16.30
RoundysRNDY20.20
CempraCEMP14.56

This week there are only three IPOs planned. Let’s take a look at each:

Ceres (NASDAQ:CERE). The company sells seeds to produce renewable bioenergy feedstocks, which helps reduce reliance on petroleum fuels.

But Ceres� products are still in the early stages, and sales were only $6.6 million last year, with a net loss of $36.3 million.

The lead underwriter on the deal is Goldman Sachs (NYSE:GS). Ceres plans to issue 5 million shares at a price range of $16 to $17 each, which is down from the prior range of $21 to $23 (indicating soft demand for the transaction).

Brightcove (NASDAQ:BCOV). The company develops a cloud-based platform that allows companies to distribute and manage videos as well as mobile apps.

From 2008 to 2011, revenues jumped from $24.5 million to $63.6 million. But there was a loss of $17.3 million last year.

The company plans to sell 5 million shares at a price range of $10 to $12. The lead underwriter is Morgan Stanley (NYSE:MS).

TVAX Biomedical (NASDAQ:TVAX). This biotech focuses on the development of targeted cell-based treatments for cancer. This involves the use of a cancer cell vaccination and the activation of killer T cells.

After the public offering, the company plans to run a Phase III clinical trial.

TVAX plans to sell 2 million shares at a range of $9 to $11. The lead underwriter is Roth Capital.

Tom Taulli runs the InvestorPlace blog�IPO Playbook, a site dedicated to the hottest news and rumors about initial public offerings. He also is the author of��The Complete M&A Handbook”,��All About Short Selling��and��All About Commodities.��Follow him on Twitter at�@ttaulli�or reach him via�email. As of this writing, he did not own a position in any of the aforementioned securities.

No comments:

Post a Comment